This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia
Voluntary written informed consent and willingness to comply with all study procedures
Age ≥ 18 years
Confirmed diagnosis of acute myeloid leukemia (AML)
Patients with R/R AML with NPM1-m
Diagnosis of acute promyelocytic leukemia.
Donor lymphocyte infusion < 30 days prior to study entry.
Clinically active central nervous system (CNS) leukemia.
Prior hematopoietic stem cell transplantation (HSCT) without adequate hematologic recovery.